Prostate artery embolization assessed in Swedish South East healthcare region

16

Oct 2019

In Sweden, the County Councils are grouped into six healthcare regions to facilitate cooperation and to maintain a high level of advanced medical care. One of them is the Regional Methods Council of South East healthcare region. This Council provides support for decision-making in the South East healthcare region and evaluates the scientific evidence for the introduction of new medical practices and devices in the South East healthcare region. Medicines are excluded from the scope of the assessment of the Council.

In September 2019, Regional Methods Council of South East healthcare region released a report for prostate artery embolization (PAE) for benign prostatic hyperplasia, which aimed to assess PAE in comparison to transurethral resection of the prostate (TURP) in terms of efficiency and cost-effectiveness. The Council came to the following conclusions:

  • The PAE could be performed in day surgery with the use of local anesthesia and anticoagulation treatment, whereas TURP requires hospitalization, spinal anesthesia and, in some cases, heparin injections for a period
  • Few cases of urinary incontinence and retrograde ejaculation have been reported after PAE
  • The need for blood transfusions is lower for PAE than TURP
  • The costs for PAE are lower than for TURP
  • The PAE is primarily relevant for the following groups of patients:
    • Elderly patients with comorbidities, when spinal or general anesthesia can not be used
    • Patients with prostate glands larger than 80 mL
  • The following disadvantages of PAE were determined:
    • The PAE is a technically demanding intervention with the use of X-rays and contrast agents
    • The risk of inadvertent embolization of adjacent arteries/organs
    • Possible injury of the femoral artery in the groin in the form of bleeding or clot formation
    • Aneurysm occurrence at the site of puncture
  • The following prerequisites for the introduction of PAE into the practice were outlined:
    • The good skills and interventions of radiologists
    • Well-established center
    • The operation should take place in cooperation with the urological department
  • The use of registries for follow-up of patients and registration of side effects is strongly recommended.

See the full information in Swedish here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

16

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more